Business Context and Reporting Period
Company: Regeneron Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 1999
Business Overview: Regeneron is a biotechnology company focused on discovering and developing novel therapeutics, primarily protein-based drugs and small molecules. Key programs include AXOKINE (for obesity/diabetes), BDNF and NT-3 (for ALS and constipation), and angiogenesis research. The company relies heavily on collaborations with major partners including The Procter & Gamble Company, Amgen Inc., Merck & Co., Inc., and Sumitomo Pharmaceuticals.
Key Financial Metrics
| Metric (in thousands) | Q1 1999 | Q1 1998 |
|---|---|---|
| Total Revenues | $6,918 | $8,250 |
| Net Loss | ($8,930) | ($3,829) |
| Net Loss Per Share (Basic/Diluted) | ($0.29) | ($0.12) |
| Cash and Cash Equivalents (End of Period) | $21,777 | $19,258 |
| Total Cash, Equivalents & Marketable Securities | $104,571 | Not explicitly stated for Q1 1998 |
| Net Cash Used in Operating Activities | ($8,427) | ($4,206) |
| Net Cash Provided by Investing Activities | $9,835 | ($5,007) |
| Accumulated Deficit (Cumulative) | ($186,163) | N/A |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 16% to $6.9 million from $8.3 million. This was driven by a drop in contract research revenue ($3.3M vs $4.6M) due to the cessation of revenue from the Sumitomo Pharmaceuticals collaboration in Q1 1999, which was not fully offset by increased revenue from the Procter & Gamble agreement.
- Expense Increase: Total operating expenses rose 31% to $15.8 million from $12.1 million. Research and development (R&D) expenses increased significantly to $11.2 million (from $8.2 million) due to higher staffing and increased clinical/preclinical activity.
- Widened Loss: The net loss more than doubled to $8.9 million from $3.8 million, reflecting the combination of lower revenues and higher R&D spending.
- Investment Activity: Net cash provided by investing activities turned positive ($9.8 million) compared to a use of cash ($5.0 million) in the prior year, primarily due to net sales of marketable securities ($33.7M sales vs $22.9M purchases).
Guidance, Outlook, and Risks
- Clinical Progress:
- AXOKINE: An Investigational New Drug (IND) application was filed with the FDA, and a Phase I safety study for obesity/diabetes commenced in Q1 1999. No assurance of success is given.
- BDNF/NT-3: Amgen-Regeneron Partners continued development for ALS and constipation. A multi-center subcutaneous study for ALS is expected to begin later in 1999.
- Liquidity and Funding:
- The company holds approximately $104.6 million in cash, cash equivalents, and marketable securities as of March 31, 1999.
- Management believes existing resources will meet operating needs for at least several years.
- Future funding is expected from Procter & Gamble (research support increasing to at least $6.3 million per quarter starting Q3 1999) and potential equity purchases.
- Key Risks:
- Development Risk: High risk of failure in clinical trials for AXOKINE, BDNF, and NT-3. Previous studies of the parent molecule of AXOKINE (CNTF) resulted in adverse events.
- Collaboration Risk: Termination of agreements with Procter & Gamble or Amgen could materially adversely affect operations.
- Year 2000 (Y2K): The company is evaluating Y2K compliance for its systems and vendors. While no material issues have been found in computer systems to date, the analysis of embedded systems and vendor readiness is incomplete. Failure of third parties (e.g., utilities, collaborators) to be Y2K compliant could disrupt operations.
- Intellectual Property: Ongoing interference proceedings regarding CNTF patents with Synergen (acquired by Amgen) were resolved via a covenant not to sue in March 1998, but patent prosecution costs remain substantial.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $104.6 million cash position against the projected increase in quarterly R&D expenses and capital contributions to Amgen-Regeneron Partners.
- Procter & Gamble Milestones: Confirm the timing and conditions for the increased quarterly research support ($6.3M) and potential equity purchases under the P&G agreement.
- AXOKINE Safety Data: Monitor the results of the Phase I safety study for AXOKINE, specifically regarding antibody creation and adverse events, given the history of the parent molecule.
- Sumitomo Revenue Resumption: Track when the company expects to resume supplying BDNF to Sumitomo Pharmaceuticals to restore that revenue stream.
- Y2K Contingency: Review the final status of the Year 2000 contingency plan, particularly regarding critical vendors and embedded systems in manufacturing equipment.